HAEMONETICS CORPORATION (NYSE:HAE) Files An 8-K Results of Operations and Financial Condition

On May 7, 2019, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter>and year ended March 30, 2019. A copy of the release is furnished with this report as Exhibit 99.1.

The foregoing information, including the exhibit attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

HAEMONETICS CORP Exhibit
EX-99.1 2 ex991-q4mar2019earningsrel.htm EXHIBIT 99.1 Exhibit    Exhibit 99.1    Earnings Release FY19 Q4Investor ContactsMedia Contact  Gerry Gould,…
To view the full exhibit click here

About HAEMONETICS CORPORATION (NYSE:HAE)

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.